881
Based on prior data suggesting that scheduling alterations of platinum would increase activity, the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin in PROC patients.
 PROC patients: Subject; potential therapeutic benefit: Effect; phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin: Treatment; phenoxodiol: Treatment.Drug; carboplatin: Treatment.Drug; PROC: Treatment.Disorder; weekly: Treatment.Freq; carboplatin: Combination.Drug; phenoxodiol: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 PROC patients: Subject; potential therapeutic benefit: Effect; phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin: Treatment; phenoxodiol: Treatment.Drug; carboplatin: Treatment.Drug; PROC: Treatment.Disorder; weekly: Treatment.Freq; carboplatin: Combination.Drug; phenoxodiol: Combination.Drug